Heron Therapeutics, Inc. (HRTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on August 6, 2025, by Heron Therapeutics, Inc., a Delaware corporation. The report details the entry into a Material Definitive Agreement regarding the manufacturing and supply of specific products.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a contractual commitment rather than financial performance results.
Material Changes and Agreements
- Framework Agreement: On August 6, 2025, the Company entered into a Framework Agreement with Patheon Austria GmbH & Co KG ("Patheon") and Thermo Fisher Scientific Inc.
- Supply Commitment: Heron Therapeutics has committed to purchase 38,400 kg of specific products from Patheon through December 31, 2026.
- Services: Patheon will continue to perform ongoing stability studies and provide warehousing services for the products.
- Termination of Prior Agreements: The Framework Agreement terminated certain previous agreements and historical obligations between the parties.
- Governing Terms: The arrangement is subject to the terms of an Amended Manufacturing and Supply Agreement (Amended MSA).
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard contractual obligations. The full text of the Framework Agreement is expected to be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2025.
Key Facts for Investor Verification
- Verify the specific identity of the "Products" covered under the 38,400 kg commitment.
- Review the full text of the Framework Agreement and Amended MSA once filed in the Q3 2025 10-Q to understand pricing terms and termination clauses.
- Assess the impact of the terminated historical obligations on the Company's prior liabilities.
- Confirm the role of Thermo Fisher Scientific Inc. in the agreement, as their involvement is limited to specified purposes.